The third target of development strategy is, through the R&D of innovative drugs, then conducting domestic and international registration and patent authorization in foreign markets, to make Yiling Pharma be a large multinational pharmaceutical enterprise with the core competitiveness of innovative drugs and advanced technology platform , At present, 27 products have been approved by China NMPA and US FDA, including 11 products passed generic quality consistency evaluation.
In terms of R&D, Yiling Group attaches great importance to independent R&D activity of innovative chemical drugs, and will continue to speed up screening and approval of new projects, enrich pipelines, and improve product layout on the basis of current achievement of new drug R&D. In cardiovascular and other key areas, Yiling Group has following projects steadily advancing: 4 innovative drugs in the clinical stage, 1 innovative drug in the pre-clinical stage, and several innovative drugs in the screening and drug resistance evaluatioaddition to innovative drugs, Yiling Group also strengthens the layout of high-end improved new drugs, including long-acting release preparations, transdermal preparations and inhalation preparations, covering the fields of respiratory diseases, cardiovascular diseases, diabetes, cancer and reproductive diseases.
Based on a strong R&D team and full equipped facilities, taking a high starting point, high standard, Yiling Pharma builds innovative high-end technology incubation base, and provide multiple kinds of services for domestic and foreign enterprises, including contract sales service, contract manufacture for clinical sample and commercial production. Yiling Pharma will broaden management pattern, grasp market initiative, gradually build a global chemical drug research and development center and production and sales base, and constantly improve its own enterprise drug integrated innovation technology and international development capacity of API and formulations.
Yiling Group, as one of top pharmaceutical industry companies, is a high content of science and technology enterprises, since its inception has always been scientific and technological innovation as a driving point, the investment in scientific research increased year after year, 2016 ~ 2021 R&D investment amount of 240 million yuan, 260 million yuan, 360 million yuan, 520 million yuan, 740 million yuan, 838 million yuan. A number of breakthrough achievements have been made to solve one problem after another in the medical field. In future, Yiling Group will continue to make breakthroughs in the three major sectors of Traditional Chinese medicine, chemical &biological medicine and healthcare industry to benefit more people.